solid tumour
Exicure lists on Nasdaq, raising $55m for cancer, neurology push
Phil Taylor
Exicure, immuno-oncology, rna therapeutics, solid tumour
0 Comment
X
Exicure lists on Nasdaq, raising $55m for cancer, neurology push
https://pharmaphorum.com/news/exicure-lists-on-nasdaq-raising-55m-for-cancer-neurology-push/
Novartis’ severe aplastic anaemia drug fast-tracked by FDA
Linda Banks
blood disorder, cancer, Novartis, Priority Review, Promacta, SAA, severe aplastic anaemia, solid tumour
0 Comment
The FDA has accepted Novartis’ supplemental New Drug Application (sNDA) and granted Priority Review designation to Promacta (eltrombopag) in combination with standard immunosuppressive therapy (IST) for first-line treatment of severe aplastic anaemia (SAA), a rare and serious blood condition.
X
Novartis’ severe aplastic anaemia drug fast-tracked by FDA
https://pharmaphorum.com/news/novartis-severe-aplastic-anaemia-fda/